Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-13
2011-11-29
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
08067372
ABSTRACT:
Provided are Aβ peptide fragments that are useful in inhibiting angiogenesis. Also provided are methods for the treatment of pathological or unwanted angiogenesis and conditions and diseases associated therewith by administering an effective amount of an Aβ fragment. In a particular embodiment, the peptide fragment includes the sequence HHQKLVFF.
REFERENCES:
patent: 3105009 (1963-09-01), Roberts
patent: 5434050 (1995-07-01), Maggio et al.
patent: 5981471 (1999-11-01), Papathanassiu et al.
patent: 6043283 (2000-03-01), Giulian
patent: 7589168 (2009-09-01), Paris et al.
patent: 2003/0077261 (2003-04-01), Paris et al.
patent: 94/10569 (1994-05-01), None
patent: 94/12627 (1994-06-01), None
patent: 96/28471 (1996-03-01), None
patent: 96/12736 (1996-05-01), None
patent: 97/21728 (1997-06-01), None
patent: 98/11923 (1998-03-01), None
patent: 01/39796 (2001-06-01), None
patent: 01/76558 (2001-10-01), None
patent: 03/014329 (2003-02-01), None
patent: WO03/014329 (2003-02-01), None
patent: 03/082266 (2003-10-01), None
patent: 2007/059000 (2007-05-01), None
Wadler et al. Antineoplastic Activity of the Combination of Interferon and Cytotoxic Agents against Experimental and Human Malignancies: A Review. Cancer Research, Jun. 15, 1990, vol. 50, pp. 3473-3486.
Thorne, et al., “Delivery of Neurotrophic Factors to the Central Nervous System”, (2001) Clin. Pharmacokinet., 40 (12): 907-946.
Griffioen, et al.,“Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation”, (2000) Pharmacological Reviews, 52 (2): 237-268.
Vagnucci et al.,“Alzheimer's disease and angiogenisis”, (2003) Lancet, 361: 605-607.
Sivakumar, et al., “Modulating Angiogenesis More vs Less”, (2004) JAMA, 292(8): 972-977.
Comments (2003), “Alzheimer's disease and angiogenesis”, Lancet, 361 (9365) 1298-1300.
Rudinger J. “Characteristics of the amino acids as components of a peptide hormone sequence” (1976), University Park Press, Baltimore, MD., 1-7.
Bowie, et al “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions” (1990) Science, 247: 1306-1310.
International Search Report for PCT/US2006/043921 dated Mar. 20, 2008.
Findeis et al., “Modified-Peptide Inhibitors of Amyloid B-Peptide Polymerization” Biochemistry 38(21), 1999, 6791-6800.
Paris, et al., Society for Neuroscience Abstracts 27, 2001, 925.
Paris, et al., “Anti-angiogenic activity of the mutant Dutch AB peptide on human brain microvascular endothelial cells” Molecular Brain Research 136(2), 2005, 212-230.
Supp. EP Search Report for EP 06 83 7407 dated Oct. 26, 2009.
Supp. EP Search Report for EP 02 75 9452 dated Apr. 27, 2006.
International Search Report for PCT/US02/27040 dated Oct. 29, 2003.
International Search Report for PCT/US2009/045079 dated Jan. 22, 2010.
Goldbrunner et al., “Models for Assessment of Angiogenesis in Gliomas,” Journal of Neuro-Oncology 50, 2000, pp. 53-62.
Sausville, et al., “Contributions of Human Tumor Xenografts to Anticancer Drug Development,” Cancer Res. 66(7), 2006, 3351-3354.
Suggitt, et al., “50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches,” Clinical Cancer Research, vol. 11, 2005, 971-981.
Fidler, Isaiah J., “Regulation of Neoplastic Angiogenesis,” Journal of the National Cancer Institute Monographs, vol. 28, 2000, 10-14.
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand, eds., 1994, 491-495.
Mendis, D. B. et al. “SPARC/Osteonectin mRNA is induced in Blood Vessels Following Injury to the Adult Rat Cerebral Cortex” Neurochemical Res., 1998, 23(8): 1117-1123.
Tarkowski et al., “Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia.” Neurobiology of Aging. 2002, vol. 23, 237-243.
Paris et al., “Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway.” Neurobiology of Aging. 2000, vol. 21, 183-197.
Paris D. et al., “Inhibition of Angiogenesis by AB Peptides” Angiogenesis, 2004, 7:75-85.
Ho L. et al. “The Alternatively Spliced Kunitz Protease Inhibitor Domain Alterns Amyloid B Protein Precursor Processing and Amyloid B Protein Production in Cultured Cells”, J. Biol. Chem., 1996; 271 (48): 30929-30394.
Ramakrishnan et al., 2001, Targeting tumor vasculature using VEGF-toxin Conjugates. Methods Mol Biol 166: 219-234.
De Sauvage, F. et al. “Novel mRNA of the A4 Amyloid Precursor Gene Coding for a Possibly Secreted Protein” Science, 1989, 245(4918): 651-653.
Ellis, R. J. et al. “Cerebral amyloid angiopathy in the brains of patents with Alzheimer's disease: The CERAD experience, part XV” Neurology, 1996, 46: 1592-1596.
Folkman, J. “How is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?—G.H.A. Clowes Memorial Award Lecture” Cancer Research, Feb. 1986, 46:467-473.
Folkman, J. “What is the Evidence That Tumors Are Angiogenesis Dependent?” Journal of the National Cancer Institute, Jan. 3, 1990, 82(1): 4-6.
Hashimoto, T. et al. “Abnormal Balance in the Angiopoietin-Tie2 System in Human Brain Arteriovenous Malformations” Circ. Res. 2001, 89:111-113.
Hashimura, T. et al., “Morphological Changes of Blood Vessels in the Brain with Alzheimer's Disease” Jpn. J. Psychiatry Neurol., 1991, 45 (3): 661-665.
Johnson, K. and M. S. Albert “Perfusion abnormalities in prodromal AD” Neurobiology of Aging, 2000, 21:289-292.
Kalaria, R.N. “The Blood-Brain Barrier and Cerebrovascular Pathology in Alzheimer's Disease” Ann. N. Y. Acad. Sci., 1999, 893:113-125.
Kimura, T. et al. “Observations of Microvessels in the Brain with Alzheimer's Disease by the Scanning Electron Microscopy” Jpn. J. Psychiatry Neurol., 1991, 45(3): 671-676.
Kruger, E. A. et al. “Endostatin Inhibits Microvessel Formation in the ex Vivo Rat Aortic Ring Angiogenesis Assay” Biochem. Biophys. Res. Commun., 2000, 268:183-191.
Nagata, K. et al. “Vascular and metabolic reserve in Alzheimer's disease” Neurobiology of Aging, 2000, 21:301-307.
Naidu, A. et al. “B-Amyloid Peptide produced in Vitro Is Degraded by Proteinases Related by Cultured Cells” J. Biol. Chem., 1995, 270(3): 1369-1374.
Nicosia, R. F. et al. “Large-vessel endothelium switches to a microvascular phenotype during angiogenesis in collagen gel culture of rat aorta” Atherosclerosis, 1992, 95: 191-199.
Nicosia, R. F. et al., “Endogenous Regulation of Angiogenesis in the Rat Aorta Model” Amer. J. Path., Nov. 1997, 151(5): 1379-1386.
Ponte, P. et al., “A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors” Nature, Feb. 1988 331:525-527.
Sisodia, S. et al. “Role of the B-amyloid Protein in Alzheimer's disease” FASEB. J., 1995, 9:366-370.
Slevin, M. et al., “Serial Measurement of Vascular Endothelial Growth Factor and Transforming Growth Factor-B1 in Serum of Patients With Acute Ischemic Stroke” Stroke, 2000, 31: 1863-1870.
Weidner, N. et al., “Tumor Angiogenesis and Metastas—Correlation in Invasion Breast Carcinoma” The New England Journal of Medicine, 1991, 324(1):1-8.
Yoshikai, S. et al. “Genomic organization of the human amyloid beta-protein precursor gene” Gene, 1990, 87:257-263.
Flood J. F. et al., “Amnestic effects in mice of four synthetic peptides homologous to amyloid B protein from patients with Alzheimer disease” Proceedings of the National Academy of Sciences, USA (1991)88 (8): 3363-3366.
Tjernberg, L.O. et al. “Arrest of B-Amyloid Fibril Formation by a Pen
Mullan Michael J.
Paris Daniel
Alzheimer's Institute of America, Inc.
Bryan Cave LLP
Cordero Garcia Marcela M
LandOfFree
Modulation of angiogenesis by A-beta peptide fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of angiogenesis by A-beta peptide fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of angiogenesis by A-beta peptide fragments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293943